Telomir Pharmaceuticals (TELO) said Thursday that a preclinical study showed "significant" age reversal effects in subjects treated with Telomir-1, a compound designed to reverse aging and support longevity.
Among the effects were increased lifespan, improved mobility, and a measurable reversal of biological age markers, according to Telomir.
The company said it is collaborating with the Progeria Foundation to evaluate the effects of Telomir-1 on human progeria cell lines to advance the development of the compound as a potential treatment for children with progeria, a genetic disorder that causes accelerated aging.
Shares of Telomir Pharmaceuticals rose more than 12% in early trading Thursday.
Price: 4.74, Change: +0.54, Percent Change: +12.86
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.